cv9103
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2009 (NCT00831467)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cv9103
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00906243 | Phase 1/Phase 2 (Phase 2) | May 1, 2009 | CureVac AG, University of Florida |
| NCT00831467 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2009 | CureVac AG |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CureVac AG | For profit | 2 | 1 | 1 | 2009 |
| University of Florida | Academic/Hospital | 1 | 1 | 1 | 2009 |
2 organizations
Page 1 / 1